LOGOPHARM GmbH provides specialised services in proteomic target and biomarker R&D with a strong focus on membrane proteins and antibodies.
Founded in 2005 as a spinout of the University of Freiburg, Germany, the company combines most advanced technology and instrumentation with long-term experience in membrane protein analysis and molecular physiology to tackle even the most challenging targets, like ion channels, G-protein coupled receptors or other membrane receptors and transporters. Molecular characterisation of these targets delivers relevant information for drug development, such as post-translational modifications, subunit composition, interaction partners or changes in abundance.
The underlying proteomic approach is distinct from current high-throughput technologies that are based on recombinant systems and therefore suffer from high error rates, in that:
The leading performance of our technology has been well documented in numerous scientific publications.
Customers and partners may also benefit from our large internal database (more than 2,000 fully MS-analysed affinity purifications of membrane proteins and their interactors, covering a major portion of the mammalian proteome), our network of distinguished scientific collaborators, and reasonable policies concerning pricing and deal structures.